ReviewFrontiers in immunology2022
Cardiovascular Involvement in Sjögren's Syndrome.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 33 citations in OpenAlex.
- A cardiac debut: Myocarditis revealing seronegative primary Sjögren's syndrome in a young woman-A case report.Radiology case reports · 2026Article
- Pediatric Sjögren's Disease: Literature Review and Diagnostic Challenges in an Uncommon Case.Diagnostics (Basel, Switzerland) · 2026Article
- Major adverse cardiovascular events in Sjögren's disease: incidence, associated factors, and impact on mortality in a prospective multicenter cohort.Rheumatology international · 2026Article
- Triglyceride-glucose index and anti-Ro52 antibody for identification of cardiovascular disease in patients with primary Sjögren's disease.Lipids in health and disease · 2026Article
- Association of Vitamin D Deficiency with Mortality and Cardiorenal Events in Sjögren's Syndrome and Osteoporosis.Journal of clinical medicine · 2026Article
- Sjogren's Disease-Aspects of Clinical Disease Beyond Dry Eyes/Mouth.Journal of clinical medicine · 2026Review
- Hemoglobin-to-Red Cell Distribution Width Ratio and Vitamin D Status as Early Predictors of Cardiovascular Risk in Primary Sjögren's Syndrome.Life (Basel, Switzerland) · 2026Article
- Risk of venous, arterial, and rare thrombotic events in adults with Sjögren's disease: a systematic review and meta-analysis.Reumatologia · 2026Review
- Deciphering the interferon gene signature spectrum: association with the clinical heterogeneity of Sjögren's disease.Frontiers in immunology · 2026Article
- Sjogren's Disease and Elevated Cardiovascular Risk: Mechanisms and Treatment.Journal of cardiovascular development and disease · 2025Review
- Sjögren's Syndrome Presenting With Multiorgan Extraglandular Manifestations: A Case Report.Cureus · 2025Article
- Article
- Insights into Pulmonary Arterial Hypertension in Connective Tissue Diseases.Journal of clinical medicine · 2025Review
- Incidence of secondary pericardial effusions associated with different etiologies: a comprehensive review of literature.Journal of cardiothoracic surgery · 2025Review
- Biopsy-proven acute eosinophilic myocarditis as the initial manifestation of severe primary Sjögren's syndrome: a case report.Frontiers in cardiovascular medicine · 2025Article
- Using the Immune System for Effective Periodontal and Caries Management.BioMed research international · 2025Review
- No difference in endothelial microvasculation measured by peripheral arterial tonometry in patients with Sjögren's disease and matched controls.Frontiers in medicine · 2025Article
- Neurological involvement in primary Sjögren's syndrome: a retrospective analysis of clinical, radiological, laboratory and therapeutic correlations.BMJ neurology open · 2025Article
- Causal associations of Sjögren's syndrome with cardiovascular disease: A two-sample Mendelian randomization study.American heart journal plus : cardiology research and practice · 2024Article
- Endothelial Dysfunction in Primary Sjögren's Syndrome: Correlation with Serum Biomarkers of Disease Activity.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sjögren Syndrome (SS) seems to be associated with a greater "overall risk" of cardiovascular (CV) and cerebrovascular events. Although not conventionally considered a feature of the disease, CV events represent a major burden in SS patients. CV risk is the consequence of a complex combination of multiple factors, including traditional risk factors and disease-related mechanisms. A complex relationships between disease-related features, endothelial dysfunction and traditional risk factor has been suggested. Several drugs are available for treating the systemic manifestations of SS, however they have shown positive effects on different outcomes of the disease, but until today the data on the role of these drugs on CV events are scarse. Given these data, the aim of this review was to evaluate the risk of CV risk in primary SS and the effect of the drugs on this manifestation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.